Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of adjunctive zonisamide for primary generalized tonic-clonic seizures
ACTRN12608000516381Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of zonisamide in epilepsy and generalized tonic-clonic seizure (GTCS), sponsored by Eisai Co., Ltd. Primary endpoint: Long-term safety of zonisamide. Started Jan 2009; status: terminated.
02
Drugs
zonisamide
03
Conditions
epilepsygeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on ACTRN12608000516381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000516381.